6.
Bruix J, Qin S, Merle P, Granito A, Huang Y, Bodoky G
. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2016; 389(10064):56-66.
DOI: 10.1016/S0140-6736(16)32453-9.
View
7.
Schulze K, Imbeaud S, Letouze E, Alexandrov L, Calderaro J, Rebouissou S
. Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. Nat Genet. 2015; 47(5):505-511.
PMC: 4587544.
DOI: 10.1038/ng.3252.
View
8.
Lanini S, Easterbrook P, Zumla A, Ippolito G
. Hepatitis C: global epidemiology and strategies for control. Clin Microbiol Infect. 2016; 22(10):833-838.
DOI: 10.1016/j.cmi.2016.07.035.
View
9.
Qin S, Chen M, Cheng A, Kaseb A, Kudo M, Lee H
. Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2023; 402(10415):1835-1847.
DOI: 10.1016/S0140-6736(23)01796-8.
View
10.
Behari J, Gougol A, Wang R, Luu H, Paragomi P, Yu Y
. Incidence of hepatocellular carcinoma in nonalcoholic fatty liver disease without cirrhosis or advanced liver fibrosis. Hepatol Commun. 2023; 7(7).
PMC: 10319365.
DOI: 10.1097/HC9.0000000000000183.
View
11.
Zhang B, Yang B, Tang Z
. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol. 2004; 130(7):417-22.
DOI: 10.1007/s00432-004-0552-0.
View
12.
Llovet J, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J
. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359(4):378-90.
DOI: 10.1056/NEJMoa0708857.
View
13.
Zhu A, Kang Y, Yen C, Finn R, Galle P, Llovet J
. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019; 20(2):282-296.
DOI: 10.1016/S1470-2045(18)30937-9.
View
14.
Nagtegaal I, Odze R, Klimstra D, Paradis V, Rugge M, Schirmacher P
. The 2019 WHO classification of tumours of the digestive system. Histopathology. 2019; 76(2):182-188.
PMC: 7003895.
DOI: 10.1111/his.13975.
View
15.
Tang A, Bashir M, Corwin M, Cruite I, Dietrich C, Do R
. Evidence Supporting LI-RADS Major Features for CT- and MR Imaging-based Diagnosis of Hepatocellular Carcinoma: A Systematic Review. Radiology. 2017; 286(1):29-48.
PMC: 6677284.
DOI: 10.1148/radiol.2017170554.
View
16.
Orci L, Sanduzzi-Zamparelli M, Caballol B, Sapena V, Colucci N, Torres F
. Incidence of Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review, Meta-analysis, and Meta-regression. Clin Gastroenterol Hepatol. 2021; 20(2):283-292.e10.
DOI: 10.1016/j.cgh.2021.05.002.
View
17.
Imamura H, Matsuyama Y, Tanaka E, Ohkubo T, Hasegawa K, Miyagawa S
. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol. 2003; 38(2):200-7.
DOI: 10.1016/s0168-8278(02)00360-4.
View
18.
Cheng A, Kang Y, Chen Z, Tsao C, Qin S, Kim J
. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2008; 10(1):25-34.
DOI: 10.1016/S1470-2045(08)70285-7.
View
19.
Zou J, Zhang L, Ren Z, Ye S
. Efficacy and safety of cTACE versus DEB-TACE in patients with hepatocellular carcinoma: a meta-analysis. J Dig Dis. 2016; 17(8):510-517.
DOI: 10.1111/1751-2980.12380.
View
20.
Chiang D, Villanueva A, Hoshida Y, Peix J, Newell P, Minguez B
. Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res. 2008; 68(16):6779-88.
PMC: 2587454.
DOI: 10.1158/0008-5472.CAN-08-0742.
View